Anixa Biosciences receives South Korean patent for breast cancer vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
June 29, 2026 8:45 AM EDTComposition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate
Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients
SAN JOSE, Calif., June 29, 2026 /PRNewswire/... More
